Drugmaker Eisai to withdraw weight loss drug Belviq after trials find cancer link
Eisai Co. will withdraw its weight loss drug Belviq after the US Food and Drug Administration said clinical trials showed an increased incidence of cancer among users, the company said.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Health | Weight Loss